When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases.
Suryaprasad
Anil
A
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA.
Stone
John H
JH
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D019072:Antibiotic Prophylaxis / Q000379:methods*; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D045363:Pneumocystis carinii / Q000276:immunology; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000276:immunology / Q000517:prevention & control*
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents